Stock Analiz

LLY vs NVO stock comparison

ELI LILLY & Co vs. Novo Nordisk A S · data as of November 13, 2026

ELI LILLY & Co (LLY) has a market value of about $1.36T, Novo Nordisk A S (NVO) about $184.3B. Over their latest twelve months ELI LILLY & Co had revenue of $86.5B and Novo Nordisk A S $49.2B.

Both score 3.4 out of 5 on our five checks.

By area, the stronger company is Novo Nordisk A S on value; ELI LILLY & Co on future growth; ELI LILLY & Co on shareholder returns.

Novo Nordisk A S is cheaper on earnings (P/E 11.1 vs. 46.9), while ELI LILLY & Co grew revenue faster over five years (21.6% vs. 18.4% a year).

ELI LILLY & Co leads on 7 of the compared lines and Novo Nordisk A S on 14.

Side by side

LLYNVO
Size and price
Market cap$1.36T$184.3B
Share price$1,443.50$41.63
Score
Overall score (of 5)3.43.4
Value03
Future growth53
Track record55
Financial health33
Shareholder returns43
Valuation
P/E (TTM)46.911.1
Forward P/E30.412.1
Price / free cash flow69.127.8
Price / sales15.73.7
EV / EBITDA37.17.4
PEG1.700.57
DCF value vs. price−37%−37%
Business
Revenue$86.5B$49.2B
Net income$27.6B$16.7B
Free cash flow$19.7B$6.6B
Net margin31.9%33.9%
Gross margin (5-yr avg.)78.9%83.5%
ROIC (5-yr avg.)22.9%47.5%
Growth
Revenue growth (1 yr)44.7%20.2%
Revenue growth (5 yrs, per year)21.6%18.4%
EPS growth (5 yrs, per year)27.6%19.5%
Balance sheet and payouts
Net cash (cash minus debt)-$44.6B-$13.0B
Dividend yield0.48%4.32%
Shareholder yield0.8%4.4%
Analysts
Upside to average target+1%—
Consensus ratingBuyHold

Highlighted = the better figure on that line. Revenue, net income and free cash flow: LLY TTM to September 30, 2026, NVO TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, ELI LILLY & Co or Novo Nordisk A S?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) ELI LILLY & Co scores 3.4 out of 5 and Novo Nordisk A S 3.4; the table shows where each one is stronger.

Is ELI LILLY & Co cheaper than Novo Nordisk A S?

On trailing earnings, Novo Nordisk A S trades at a P/E of 11.1 and ELI LILLY & Co at 46.9, so Novo Nordisk A S is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, ELI LILLY & Co or Novo Nordisk A S?

Over five years ELI LILLY & Co grew revenue about 21.6% a year and Novo Nordisk A S about 18.4% a year.

Which pays a higher dividend?

ELI LILLY & Co yields 0.48% and Novo Nordisk A S 4.32%.

Full ELI LILLY & Co analysis → Full Novo Nordisk A S analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.